Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Author(s): Aditya Bardia, MD, PhD1; Ian E. Krop, MD, PhD2,3; Takahiro Kogawa, MD, PhD4; Dejan Juric, MD1; Anthony W. Tolcher, MD5,6,7; Erika P. Hamilton, MD8,9; Toru Mukohara, MD, DMedSci10; Aaron Lisberg, MD11; Toshio Shimizu, MD, PhD12,13; Alexander I. Spira, MD14; Junji Tsurutani, MD, PhD1; Senthil Damodaran, MD, PhD15; Kyriakos P. Papadopoulos, MD16; Jonathan Greenberg, MD, MA, BA17,18; Fumiaki Kobayashi, PhD, MS22; Hong Zebger-Gong, MD, PhD18; Rie Wong, BS20; Yui Kawasaki, PhD17; Tadakatsu Nakamura, MS19; Funda Meric-Bernstam, MD15
Source: https://doi.org/10.1200/JCO.23.01909

Dr. Anjan Patel's Thoughts

Datopotamab Deruxtecan is a new ADC that will likely be approved in the near future. The payload is the same as used in Enhertu, but the antibody is directed at TROP2. This report is from the TROPION-pan tumor study and shows a promising ORR in HR+/HER2- MBC. There is reasonable data for this compound in 2L met-NSCLC in the TROPION-LUNG01 study with an improvement in PFS compared to docetaxel of 4.4 vs 3.7 months. Dato also is effective in patients with actionable genetic alterations in the 2L setting. There is also an ongoing study on its use in the 1L setting for met-NSCLC in combination with pembrolizumab and chemotherapy.

PURPOSE

Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker.

PATIENTS AND METHODS

TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors. The primary study objective was to assess the safety and tolerability of Dato-DXd. Secondary objectives included evaluation of antitumor activity and pharmacokinetics. Results from patients with advanced/metastatic hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer (BC) or triple-negative BC (TNBC) are reported.

RESULTS

At data cutoff (July 22, 2022), 85 patients (HR+/HER2– BC = 41, and TNBC = 44) had received Dato-DXd. The objective response rate by blinded independent central review was 26.8% (95% CI, 14.2 to 42.9) and 31.8% (95% CI, 18.6 to 47.6) for patients with HR+/HER2– BC and TNBC, respectively. The median duration of response was not evaluable in the HR+/HER2– BC cohort and 16.8 months in the TNBC cohort. The median progression-free survival in patients with HR+/HER2– BC and TNBC was 8.3 and 4.4 months, respectively. All-cause treatment-emergent adverse events (TEAEs; any grade, grade ≥3) were observed in 100% and 41.5% of patients with HR+/HER2– BC and 100% and 52.3% of patients with TNBC. Stomatitis was the most common TEAE (any grade, grade ≥3) in both HR+/HER2– BC (82.9%, 9.8%) and TNBC (72.7%, 11.4%) cohorts.

CONCLUSION

In patients with heavily pretreated advanced HR+/HER2– BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.

Author Affiliations

1Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 2Yale Cancer Center, New Haven, CT; 3Dana-Farber Cancer Institute, Boston, MA; 4Department of Advanced Medical Development, Cancer Institute Hospital of JFCR, Tokyo, Japan; 5South Texas Accelerated Research Therapeutics, San Antonio, TX; 6NEXT Oncology, San Antonio, TX; 7Texas Oncology, San Antonio, TX; 8Sarah Cannon Research Institute, Nashville, TN; 9Tennessee Oncology, PLLC, Nashville, TN; 10Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 11Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA; 12Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; 13Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Hospital, Wakayama, Japan; 14Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA; 15Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; 16Clinical Research, START, San Antonio, TX; 17Global Oncology Clinical Development, Daiichi Sankyo, Inc, Basking Ridge, NJ; 18Global Oncology Clinical Development, Daiichi Sankyo Europe GmbH, Munich, Germany; 19Data Intelligence, Daiichi Sankyo, Co, Ltd, Tokyo, Japan; 20Global Oncology Clinical Development, Daiichi Sankyo, Co, Ltd, Tokyo, Japan

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

This study confirms what we saw in initial reports showing the addition of pembro increasing the rate of ypathological complete response (ypCR’s) in the neoadjuvant setting for triple-negative breast cancer (TNBC). New data shows a 5% improvement (87 vs 82%) in overall survival (OS) with the quadruplet. Higher gains but at higher cost of toxicity. The fact that adjuvant intraosseous (IO) does not seem to improve outcomes, but neoadjuvant chemo+IO does show intact tumor-immune interactions to create maximum treatment effectiveness is most likely real. Of note, this seems mostly independent of programmed death-ligand 1 (PDL1) status.

Read More »